The biotech finance sector remains in retroactive mode, with money reaching shareholders and companies through corporate mergers and deals rather than through venture capital or public market financing.
8 billion, Merck paid an 81% premium for Prometheus Bioscience and its anti-inflammatory assets. Meanwhile, the quarter’s top venture round went to ElevateBio, a gene therapy platforms provider, with a series D round that brought another $401 million to the substantial venture capital stack raised by the company since 2019.
Resumimos esta notícia para que você possa lê-la rapidamente. Se você se interessou pela notícia, pode ler o texto completo aqui. Consulte Mais informação: